Clinical Significance of Additional Cytogenetic Abnormalities (ACA) at Disease Progression in Patients with High-Risk Myelodysplastic Syndrome (MDS) Treated with Azacitidine

被引：0
|
作者：
Naito, Chiaki [1 ]
Shimizu, Hiroaki [2 ]
Miyazawa, Yuri [3 ]
Ishizaki, Takuma [4 ]
Yokohama, Akihiko [5 ]
Saito, Takayuki [6 ]
Tsukamoto, Norifumi [7 ]
Handa, Hiroshi [8 ]
机构：
[1] Gunma Univ Hosp, Dept Hematol, Maebashi, Gumma, Japan
[2] Gunma Univ, Dept Hematol, Grad Sch Med, Maebashi, Gunma, Japan
[3] Gunma Univ Hosp, Dept Hematol, Masbashi, Gunma, Japan
[4] Gunma Univ Hosp, Dept Hematol, Maebashi, Gumma, Japan
[5] Gunma Univ Hosp, Blood Transfus Serv, Maebashi, Gumma, Japan
[6] Gunma Univ, Grad Sch Hlth Sci, Maebashi, Gumma, Japan
[7] Gunma Univ Hosp, Ctr Oncol, Maebashi, Gumma, Japan
[8] Gunma Univ, Dept Hematol, Grad Sch Med, Maebashi, Gumma, Japan
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-127956
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5434
引用
收藏
页数：3
相关论文
共 50 条
  • [31] SOMATIC MUTATION DYNAMICS IN HIGH-RISK MDS PATIENTS TREATED WITH AZACITIDINE IDENTIFIED VIA SERIAL SAMPLING
    Polgarova, K.
    Vargova, K.
    Kulvait, V.
    Dusilkova, N.
    Minarik, L.
    Zemanova, Z.
    Jonasova, A.
    Stopka, T.
    HAEMATOLOGICA, 2017, 102 : 478 - 478
  • [32] Biological and clinical significance of cytogenetic abnormalities in low-risk and high-risk gastrointestinal stromal tumors
    Gunawan, B
    Bergmann, F
    Höer, J
    Langer, C
    Schumpelick, V
    Becker, H
    Füzesi, L
    HUMAN PATHOLOGY, 2002, 33 (03) : 316 - 321
  • [33] AZACITIDINE: AN ALTERNATIVE TREATMENT REGIMEN FOR ELDERLY HIGH-RISK MYELODYSPLASTIC PATIENTS
    Ramakrishna, R.
    Alexander, W.
    Sarathy, K.
    HAEMATOLOGICA, 2013, 98 : 583 - 584
  • [34] Azacitidine delivers dramatic results in patients with high-risk myelodysplastic syndromes
    不详
    EXPERT REVIEW OF HEMATOLOGY, 2009, 2 (02) : 120 - 120
  • [35] Azacitidine delivers dramatic results in patients with high-risk myelodysplastic syndromes
    Fenaux, P.
    Mufti, G. J.
    Hellstrom-Lindberg, E.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (04) : 395 - 395
  • [36] Impact Of Cytogenetics and Cytogenetic Response On Outcome In Myelodysplastic Syndromes (MDS) treated With Azacitidine (AZA). A Collaborative Study In 878 Patients
    Sebert, Marie
    Komrokji, Rami S.
    Sekeres, Mikkael A.
    Prebet, Thomas
    Cluzeau, Thomas
    Santini, Valeria
    Sanna, Alessandro
    Al Ali, Najla H.
    Hobson, Sean
    Eclache, Virginie
    List, Alan
    Fenaux, Pierre
    Ades, Lionel
    BLOOD, 2013, 122 (21)
  • [37] Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine
    Bouchla, Anthi
    Thomopoulos, Thomas P.
    Papageorgiou, Sotirios G.
    Apostolopoulou, Christina
    Loucari, Constantinos
    Mpazani, Efthimia
    Pappa, Vasiliki
    EPIGENOMICS, 2021, 13 (14) : 1129 - 1143
  • [38] Impact of Cytogenetic Abnormalities and Cytogenetic Response to Hypomethylating Agents (HMAs) in Patients (pts) with Lower Risk Myelodysplastic Syndromes (MDS)
    Montalban-Bravo, Guillermo
    Carcia-Manero, Guillermo
    Short, Nicholas J.
    Sasaki, Koji
    Sekeres, Mikkael A.
    Komrokji, Rami S.
    Steensma, David P.
    DeZern, Amy E.
    Roboz, Gail J.
    Kadia, Tapan
    Borthakur, Gautam
    DiNardo, Courtney
    Miller, Darla
    Estrov, Zeev
    Pemmaraju, Naveen
    Daver, Naval
    Konopleva, Marina
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Jabbour, Elias
    BLOOD, 2015, 126 (23)
  • [39] Prevalence and Clinical Impact of Additional Cytogenetic Abnormalities in Patients (Pts) with Myelodysplastic Syndromes (MDS) and Deletion 5q from the MDS-003 and MDS-004 Studies
    Giagounidis, Aristoteles
    List, Alan F.
    Hellstrom-Lindberg, Eva
    Mufti, Ghulam J.
    Schlegelberger, Brigitte
    Morrill, John
    Wu, Chengqing
    Skikne, Barry
    Fenaux, Pierre
    Goehring, Gudrun
    BLOOD, 2014, 124 (21)
  • [40] The Prognostic Impact of Cytogenetic Scores in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Venetoclax and Azacitidine in a Phase 1 Study
    Garcia, Jacqueline S.
    Wei, Andrew H.
    Borate, Uma
    Fong, Chun Yew
    Baer, Maria R.
    Nolte, Florian
    Peterlin, Pierre
    Jurcic, Joseph
    Jacoby, Meagan
    Hong, Wen-Jen
    Platzbecker, Uwe
    Odenike, Olatoyosi
    Cunningham, Ilona
    Zhou, Ying
    Dunbar, Martin
    Harb, Jason G.
    Popovic, Relja
    Tanwani, Poonam
    Gopalakrishnan, Sathej
    Wolff, Johannes
    Garcia-Manero, Guillermo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S315 - S316
12345